Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice

Liver cancer is associated with chronic inflammation, which is linked to immune dysregulation, disordered metabolism, and aberrant cell proliferation. Nucleoside triphosphate diphosphohydrolase‐1; (CD39/ENTPD1) is an ectonucleotidase that regulates extracellular nucleotide/nucleoside concentrations by scavenging nucleotides to ultimately generate adenosine. These properties inhibit antitumor immune responses and promote angiogenesis, being permissive for the growth of transplanted tumors. Here we show that Cd39 deletion promotes development of both induced and spontaneous autochthonous liver cancer in mice. Loss of Cd39 results in higher concentrations of extracellular nucleotides, which stimulate proliferation of hepatocytes, abrogate autophagy, and disrupt glycolytic metabolism. Constitutive activation of Ras‐mitogen‐activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR)‐S6K1 pathways occurs in both quiescent Cd39 null hepatocytes in vitro and liver tissues in vivo. Exogenous adenosine 5′‐triphosphate (ATP) boosts these signaling pathways, whereas rapamycin inhibits such aberrant responses in hepatocytes. Conclusion: Deletion of Cd39 and resulting changes in disordered purinergic signaling perturb hepatocellular metabolic/proliferative responses, paradoxically resulting in malignant transformation. These findings might impact adjunctive therapies for cancer. Our studies indicate that the biology of autochthonous and transplanted tumors is quite distinct. (HEPATOLOGY 2013)

[1]  T. Luedde,et al.  Senescence surveillance of pre-malignant hepatocytes limits liver cancer development , 2011, Nature.

[2]  V. Bohr,et al.  Metabolism, Genomics, and DNA Repair in the Mouse Aging Liver , 2011, Current gerontology and geriatrics research.

[3]  S. Robson,et al.  Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. , 2011, Neoplasia.

[4]  R. Lenkinski,et al.  On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. , 2011, Neoplasia.

[5]  Tak W. Mak,et al.  The ER UDPase ENTPD5 Promotes Protein N-Glycosylation, the Warburg Effect, and Proliferation in the PTEN Pathway , 2010, Cell.

[6]  Takashi Murakami,et al.  CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. , 2010, Gastroenterology.

[7]  D. Candinas,et al.  Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice , 2010, Hepatology.

[8]  Jing Chen,et al.  Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth , 2009, Science Signaling.

[9]  J. Kramer,et al.  Ectonucleoside Triphosphate Diphosphohydrolase Type 5 (Entpd5)-Deficient Mice Develop Progressive Hepatopathy, Hepatocellular Tumors, and Spermatogenic Arrest , 2009, Veterinary pathology.

[10]  W. Linehan,et al.  LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.

[11]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[12]  D. Candinas,et al.  Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration. , 2008, Gastroenterology.

[13]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[14]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[15]  D. Candinas,et al.  Natural killer T cell dysfunction in CD39‐null mice protects against concanavalin A–induced hepatitis , 2008, Hepatology.

[16]  K. Kotani,et al.  Deletion of Cd39/Entpd1 Results in Hepatic Insulin Resistance , 2008, Diabetes.

[17]  Y. Banz,et al.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism. , 2008, Frontiers in bioscience : a journal and virtual library.

[18]  Robin Mathew,et al.  Role of autophagy in cancer , 2007, Nature Reviews Cancer.

[19]  V. Mootha,et al.  mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.

[20]  S. Robson,et al.  Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. , 2007, The American journal of pathology.

[21]  Linda Yip,et al.  ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors , 2006, Science.

[22]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[23]  A. Usheva,et al.  RanBPM associates with CD39 and modulates ecto-nucleotidase activity. , 2006, The Biochemical journal.

[24]  Y. Ben-Neriah,et al.  NF-κB inhibition: A double-edged sword in cancer? , 2006 .

[25]  J. Thiran,et al.  Morphological Classification of Mouse Liver Tumors Based on Biological Characteristics , 2006 .

[26]  Y. Ben-Neriah,et al.  NF-kappaB inhibition: a double-edged sword in cancer? , 2006, European journal of cancer.

[27]  Raymond Sawaya,et al.  The role of autophagy in cancer development and response to therapy , 2005, Nature Reviews Cancer.

[28]  P. White,et al.  Regulation of Human Hepatocytes by P2Y Receptors: Control of Glycogen Phosphorylase, Ca2+, and Mitogen-Activated Protein Kinases , 2005, Journal of Pharmacology and Experimental Therapeutics.

[29]  S. Robson,et al.  Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. , 2005, Seminars in thrombosis and hemostasis.

[30]  R. Rodnight,et al.  ERK, PKC and PI3K/Akt Pathways Mediate Extracellular ATP and Adenosine-Induced Proliferation of U138-MG Human Glioma Cell Line , 2005, Oncology.

[31]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[32]  Vijaya R Arjunan,et al.  Extracellular ATP activates c‐jun N‐terminal kinase signaling and cell cycle progression in hepatocytes , 2004, Hepatology.

[33]  Hong Zhang,et al.  Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. , 2003, Cancer cell.

[34]  Patricia D. Christie,et al.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation , 1999, Nature Medicine.

[35]  S. Goldfarb,et al.  Hepatocarcinogenesis in the mouse. Combined morphologic-stereologic studies. , 1983, The American journal of pathology.